

HEALTHCARE MONTHLY

AUGUST 2023



Our healthcare team architects market-defining outcomes for some of the most innovative medical device, life science and diagnostics, healthcare services and pharmaceutical companies in the world.










BioTech / Pharma

Healthcare Services

Life Sciences / Diagnostics


Medical Devices

HEADLINE TRANSACTIONS


	TARGET	ACQUIROR	ACQUISITION SYNOPSISIS
BioTech / Pharma			<ul style="list-style-type: none"> • Biogen, Inc. (NASDAQ:BIIB) has reached a definitive agreement to acquire Reata Pharmaceuticals, Inc. (NYSE:RETA) • Reata Pharmaceuticals is a clinical-stage biopharmaceutical company developing small molecule therapeutics targeting novel or rare diseases, including SKYCLARIS®, the only approved treatment for Friedreich's Ataxia in the U.S. • Biogen discovers, develops, manufactures and delivers therapies targeting neurological and neurodegenerative diseases such as Alzheimer's disease, Amyotrophic Lateral Sclerosis and Multiple Sclerosis • Total Consideration: \$7.3 billion • Per share price represents a premium of ~54%
			<ul style="list-style-type: none"> • Sanofi, S.A. (NASDAQ:SNY) has reached a definitive agreement to acquire the Qunol® brand from Quten Research Institute, LLC • Qunol® is a health and wellness brand offering supplements containing CoQ10, a nutrient intended to improve heart health, and turmeric, intended to improve joint health • Sanofi, based in France, is a pharmaceutical company developing and manufacturing pharmaceuticals and vaccines as well as a portfolio of consumer healthcare products across the Allergy, Cough, Cold & Flu, Digestive Wellness, Pain Care and Physical & Mental Wellness sectors • Total Consideration: \$1.4 billion in cash
	<p>A portfolio of preclinical gene therapy products</p> 	 	<ul style="list-style-type: none"> • Alexion Pharmaceuticals, Inc., an affiliate of AstraZeneca plc (LON:AZN), has reached a definitive purchase and license agreement to acquire a portfolio of preclinical gene therapy products from Pfizer, Inc. (NYSE:PFE) • Portfolio includes several adeno-associated virus capsids, the protein shells that protect gene cargo as it is delivered into the body for gene therapy and gene editing • Alexion Pharmaceuticals develops, manufactures and markets orphan drugs to treat rare diseases • AstraZeneca is a British-Swedish holding company researching, manufacturing and selling a portfolio of products targeting major diseases in areas such as oncology, cardiovascular, respiratory, vaccines & immune therapies and rare diseases • Total Consideration: \$1.0 billion
Medical Devices			<ul style="list-style-type: none"> • Teleflex, Inc. (NYSE:TFX) has reached a definitive agreement to acquire Palette Life Sciences, A.B. • Palette Life Sciences, based in Sweden, is a privately-owned medical device and life sciences company developing urologic spacer implants and tissue bulking products for pain relief in urological and colorectal disorders • Teleflex, based in Pennsylvania, is a medical device company designing, developing, manufacturing and supplying commonly used single-use devices, including anesthesia, surgical instruments and a portfolio of interventional urology products • Total Consideration: \$650 million, consisting of \$600 million in cash and \$50 million in earnout

HEALTHCARE GROWTH & VALUATION TRENDS


Enterprise Value / LTM Revenue




Enterprise Value / LTM EBITDA



LTM Revenue Growth




LTM Gross and EBITDA Margins*



*EBITDA Margins shown as the gray line.

LTM Stock Price Index









SELECTED HEALTHCARE TRANSACTIONS

Target	Acquiror	BioTech / Pharma Transactions
DTx Pharma, Inc.	Novartis, AG (NYSE:NVS)	DTx Pharma, a biopharmaceutical company, develops small interfering RNA (siRNA) therapies for neuroscience indications including Charcot-Marie-Tooth disease type 1A Total Consideration: \$1.0 billion, consisting of \$500 million upfront and \$500 million in earnout
Two Commercial Medicines (Traverse Therapeutics Inc. (NASDAQ:TVTX))	Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)	Traverse Therapeutics, a biopharmaceutical company, is divesting its Cholbam® and Chenodal® bile acid treatment products intended to treat rare liver diseases Total Consideration: \$445 million, consisting of \$210 million in cash and \$235 million in earnout
Axolotl Biologix, Inc.	Carmell Therapeutics, Inc. (NASDAQ:CTCX)	Axolotl Biologix develops amnion-based allograft products for soft tissue repair, aesthetics and orthopedic indications Total Consideration: Axolotl's pre-merger shareholders will receive \$140 million consisting of \$65m at closing (\$8m in cash and \$57m in stock) and \$75m in earnout (\$9m in cash and \$66m in stock)

Target	Acquiror	Life Sci / Diagnostics Transactions
QDx Pathology Services, Inc. (Hadley Capital)	LabGenomics Co., Ltd (Luha Private Equity, Inc.)	QDx Pathology Services, a diagnostic laboratory, provides diagnostics services for the respiratory, digestive, urological and women's health Total Consideration: \$60 million
Kova International, Inc. (One Rock Capital Partners, LLC)	LGC Group, Ltd	Kova International, a diagnostics company, develops, manufactures and markets urinalysis and toxicology quality controls used in hospitals, quality assurance and employee wellness programs
FastPack Diagnostics Business (Qualigen Therapeutics, Inc. (NASDAQ:QLGN))	Chembio Diagnostics, Inc. (BIOSYNEX, S.A.)	Qualigen Therapeutics, a diagnostics company, is divesting FastPack®, a diagnostics platform for rapid immunoassay testing with an assay menu of ten tests including prostate cancer, thyroid function and metabolic disorders






Selected TM Capital Healthcare Experience

 <p>A PORTFOLIO COMPANY OF</p>  <p>HAS BEEN ACQUIRED BY</p> 	 <p>A PORTFOLIO COMPANY OF</p>  <p>HAS BEEN ACQUIRED BY</p> 	 <p>HAS RECEIVED A STRATEGIC INVESTMENT FROM</p> 
--	---	---

Target	Acquiror	Health Services Transactions
Bravera Health Network (Community Health Systems, Inc. (NYSE:CYH))	Tampa General Hospital (Florida Health Sciences Center, Inc.)	Bravera Health Network includes three hospitals based in Florida along with associated physician clinics and outpatient centers Total Consideration: \$280 million in cash
Blush Med Spa	Advanced Medaesthetic Partners, Inc. (Leon Capital Group)	Blush Med Spa, a multi-location medical aesthetics practice, offers injectables for the face and body, traditional spa services and branded aesthetic products to the greater Hartford, Connecticut area
Cosmetic Skin & Laser Center	Incline Equity Partners, LP	Cosmetic Skin & Laser Center, a multi-location medical aesthetics practice, offers skin rejuvenation and injectables for the face and body through locations in Northern Michigan and Southwest Florida

Target	Acquiror	Medical Device Transactions
NextPhase Medical Devices, LLC (Kidd & Company, LLC)	Arterex, Inc. (InvestIndustrial, Inc.)	NextPhase Medical Devices, a contract manufacturer, designs, develops and manufactures Class I and Class II single-use devices, electromechanical devices and active implantables
Physio-Assist, SAS (Merieux Development SAS, Turenne Capital, Inc.)	Inogen, Inc. (NASDAQ:INGN)	Physio-Assist, based in France, developed and manufactures Simeox, a technology-enabled airway clearance device used to treat bronchiectasis Total Consideration: \$45 million, consisting of \$32 million in cash and \$13 million in earnout
Tristate Biomedical Solutions, LLC	Radon Medical Imaging, LLC (5th Century Partners, LP)	Tristate Biomedical Solutions sells and services used and refurbished imaging and biomedical equipment, specializing in C-Arms and X-Rays

TM Capital's Healthcare Industry Contacts

 <p>James McLaren Managing Director jmclaren@tmcapital.com 212.809.1414</p>	 <p>Michael Goldman Managing Director mgoldman@tmcapital.com 212.809.1419</p>
 <p>John Dean Principal jdean@tmcapital.com 404.995.6234</p>	 <p>Paul Smolevitz Managing Director psmolevitz@tmcapital.com 212.809.1416</p>
 <p>Steve Hunter Managing Director, Sponsor Coverage shunter@tmcapital.com 404.995.6232</p>	